Asset Details
Do you wish to reserve the book?
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Do you wish to request the book?
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
2016
Overview
CDX2 is expressed in most colon cancers, but approximately 4% do not express this transcription factor. Lack of CDX2 expression marks a subset of cancers with a more aggressive natural history. Adjuvant chemotherapy primarily benefits patients with stage II CDX2-negative tumors.
During the past decade, disease-free survival among patients with stage III colon cancer has increased significantly owing to the introduction of new adjuvant chemotherapy regimens.
1
–
3
This therapeutic success, however, has not translated into longer disease-free survival among patients with earlier-stage (stage I or II) cancer.
4
The lack of simple, reliable criteria for the identification of patients with early-stage disease who are at high risk for relapse has made it difficult to identify patients in whom the hazards of multiagent chemotherapy may be offset by benefits with respect to disease-specific survival.
4
–
9
To address this problem, researchers have explored the . . .
Publisher
Massachusetts Medical Society
Subject
/ Antineoplastic Agents - therapeutic use
/ Biomarkers, Tumor - genetics
/ Biomarkers, Tumor - metabolism
/ Colonic Neoplasms - drug therapy
/ Colonic Neoplasms - genetics
/ Colonic Neoplasms - metabolism
/ Colonic Neoplasms - pathology
/ Female
/ Homeodomain Proteins - genetics
/ Homeodomain Proteins - metabolism
/ Humans
/ Male
/ Oligonucleotide Array Sequence Analysis
/ Patients
/ Surgery
/ Tumors
